ATI RN
ATI Pathophysiology Exam 1
1. What is a characteristic of coronary artery disease (CAD)?
- A. The build-up of infectious by-products in the lymph nodes
- B. Insufficient delivery of oxygenated blood to the myocardium
- C. Insufficient delivery of carbon dioxide to the lungs
- D. The build-up of bile in the stomach and gallbladder
Correct answer: B
Rationale: The correct characteristic of coronary artery disease (CAD) is the insufficient delivery of oxygenated blood to the myocardium. CAD is a condition where the coronary arteries become narrowed or blocked, leading to reduced blood flow to the heart muscle. This lack of oxygenated blood can result in chest pain, known as angina, and if a coronary artery becomes completely blocked, it can cause a heart attack. Choices A, C, and D are incorrect. Choice A refers to an issue related to the lymphatic system, choice C is about gas exchange in the lungs, and choice D describes a problem with bile accumulation in the digestive system, none of which are characteristics of CAD.
2. A patient is administered a nucleotide reverse transcriptase inhibitor in combination with a nonnucleotide reverse transcriptase inhibitor. What is the main rationale for administering these medications together?
- A. They improve treatment adherence.
- B. They reduce the duration of illness.
- C. They exhibit synergistic antiviral effects.
- D. They prevent opportunistic infections.
Correct answer: C
Rationale: The main rationale for administering a nucleotide reverse transcriptase inhibitor in combination with a nonnucleotide reverse transcriptase inhibitor is that they exhibit synergistic antiviral effects when used together. This combination enhances their antiviral activity against HIV by targeting different steps in the viral replication cycle. Choice A is incorrect because the rationale for combining these medications is based on their antiviral effects, not treatment adherence. Choice B is incorrect because the primary purpose of combination therapy is not to reduce the duration of illness but to improve treatment efficacy. Choice D is incorrect as the main focus of this combination is not on preventing opportunistic infections but on directly targeting the HIV virus.
3. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?
- A. Filgrastim (Neupogen)
- B. Aldesleukin (Proleukin)
- C. Interferon alfa-2b (Intron A)
- D. Darbepoetin alfa (Aranesp)
Correct answer: B
Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.
4. A patient has been using Viagra on an intermittent basis for several years. However, he has cited delays in the onset and peak of action as the occasional source of frustration. What PDE5 inhibitor may be of particular benefit to this patient's needs?
- A. Avanafil (Stendra)
- B. Tadalafil (Cialis)
- C. Vardenafil (Levitra)
- D. Alprostadil (Caverject)
Correct answer: A
Rationale: The correct answer is Avanafil (Stendra). Avanafil has a rapid onset of action compared to other PDE5 inhibitors, making it suitable for patients experiencing delays in onset and peak of action with other medications like Viagra. Tadalafil (Cialis), Vardenafil (Levitra), and Alprostadil (Caverject) do not offer the same rapid onset of action as Avanafil, making them less suitable for addressing the specific needs of this patient.
5. A female patient is concerned about the side effects of hormone replacement therapy (HRT). What common side effect should the nurse explain?
- A. Weight gain
- B. Hair loss
- C. Increased libido
- D. Decreased energy levels
Correct answer: A
Rationale: The correct answer is A: Weight gain. Weight gain is a common side effect of hormone replacement therapy (HRT) due to hormonal changes. Patients should be informed about this possibility as part of their treatment plan. Hair loss (Choice B) is not a common side effect of HRT. Increased libido (Choice C) and decreased energy levels (Choice D) are not typically associated with HRT side effects. Therefore, the nurse should focus on discussing weight gain with the patient.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access